Although INV-347 was reported safe and well tolerated in a phase 1 trial, the company cited its pharmacokinetic profile and portfolio strategy as reasons for discontinuing it. Beyond obesity, Novo Nordisk also halted development of zalfermin, a long-acting FGF21 analog for metabolic dysfunction-associated steatohepatitis (MASH). A phase 2 study combining zalfermin with semaglutide in about 700 patients did not show improvement in liver fibrosis, leading Novo to stop its development for fatty liver disease. Nonetheless, a phase 1 trial is still ongoing to gather data for potential use in Type 1 diabetes, although no further stages are planned at this time. Another casualty of portfolio rationalization is ANGPTL3i, a monoclonal antibody for dyslipidemia. Despite phase 1 data confirming safety and tolerability, development was ceased.